文献速递老年精神

锂作为痴呆疾病修饰剂的25年演变:一项叙述性综述

The 25-Year Evolution of Lithium as a Disease-Modifying Agent in Dementia: A Narrative Review.
PubMed 文献 · JAMA Psychiatry · 2026-01-01

本综述回顾了锂在轻度认知障碍(MCI)和阿尔茨海默病(AD)中作为疾病修饰剂的生物学机制与临床证据,指出低剂量锂(约0.3mM)通过多通路发挥神经保护作用,流行病学与早期随机试验提示其可能降低痴呆风险并稳定认知,支持开展低剂量乳糖酸锂的临床试验。

要点

  • 低剂量锂(约0.3mM)通过Bcl-2、BDNF、GSK-3β等多通路发挥神经保护作用。
  • 流行病学提示累积锂暴露与痴呆风险降低相关,早期MCI试验显示认知稳定及tau生物标志物改善。
  • 建议开展低剂量乳糖酸锂延缓MCI进展的前瞻性临床试验,以规避高剂量碳酸锂的肾甲状腺风险。

核心结论

  • 汇聚证据支持开展低剂量乳糖酸锂延缓MCI疾病进展的前瞻性临床试验。
  • 低剂量锂可能成为可及、廉价的治疗选择,尤其适合中低收入国家。

研究设计与样本

  • 叙述性综述,总结25年来锂作为痴呆疾病修饰剂的机制、影像、流行病学与临床试验证据。

主要发现

  • 锂通过诱导Bcl-2、增强BDNF信号、抑制GSK-3β、稳定线粒体功能及减少氧化应激发挥神经保护作用。
  • 质子磁共振波谱显示锂增加N-乙酰天冬氨酸水平,结构MRI显示锂保留灰质和/或逆转海马及皮质边缘区萎缩。
  • 低剂量锂(约0.3mM)显著低于传统精神科剂量(0.6-1.0mM),在临床前模型中刺激海马神经发生、促进结构可塑性并对抗蛋白毒性损伤。
  • 流行病学研究显示累积锂暴露与痴呆风险降低相关,早期MCI随机临床试验提示低剂量锂可稳定认知并改善tau生物标志物。
  • 再充盈假说提出锂可能作为生理微量元素发挥作用,但有待独立重复验证。

关键数值与推荐

  • 低剂量锂约为0.3mM,传统精神科剂量为0.6-1.0mM。
  • 低剂量锂在临床前模型中刺激海马神经发生、促进结构可塑性并保护对抗蛋白毒性损伤。
  • 早期MCI随机临床试验显示低剂量锂可稳定认知并改善tau生物标志物。

临床怎么用

  • 低剂量锂可能用于延缓MCI疾病进展,但需前瞻性临床试验验证。
  • 低剂量乳糖酸锂可能减少高剂量碳酸锂相关的肾脏和甲状腺风险。

局限性

  • 再充盈假说相关发现尚待独立重复验证。
  • 低剂量锂对痴呆疾病轨迹的改变仍需前瞻性临床试验证实。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

IMPORTANCE: Lithium, a long-established cornerstone therapy for bipolar disorder, is a biologically plausible disease-modifying agent for neurodegenerative disorders, including mild cognitive impairment (MCI) and Alzheimer disease (AD). OBSERVATIONS: Rather than targeting a single pathology like amyloid or tau, lithium acts across multiple cellular resilience pathways. Chronic lithium exposure induces the anti-apoptotic protein B-cell lymphoma 2 (Bcl-2), enhances brain-derived neurotrophic factor (BDNF) signaling, inhibits glycogen synthase kinase-3β (GSK-3β), stabilizes mitochondrial function, and reduces oxidative stress. These convergent mechanisms promote neuronal survival and synaptic integrity. In humans, proton magnetic resonance spectroscopy studies found that lithium increased N-acetylaspartate levels, consistent with improved neuronal viability, and structural magnetic resonance imaging (MRI) studies found that lithium preserved gray matter and/or reversed illness-related atrophy in hippocampal and corticolimbic regions. In addition, extensive evidence demonstrates that low-dose lithium (approximately 0.3mM)-significantly lower than traditional psychiatric doses (0.6-1.0mM)-exerts robust neurotrophic and neuroprotective effects. Preclinical models have found that these concentrations stimulate hippocampal neurogenesis, promote structural plasticity, and protect against proteotoxic injury. Furthermore, epidemiological studies have associated cumulative lithium exposure with reduced dementia risk, and early randomized clinical trials in MCI suggest cognitive stabilization and favorable tau biomarker changes at low, well-tolerated doses. The recent repletion hypothesis suggests that lithium may also function as a physiological trace element, but these findings await independent replication. CONCLUSIONS AND RELEVANCE: These convergent data support a prospective clinical trial of low-dose lithium orotate to slow disease progression in MCI. Such an approach would prioritize established neuroprotective mechanisms while potentially mitigating the kidney and thyroid risks associated with higher-dose carbonate formulations. If low-dose lithium can indeed meaningfully alter disease trajectory, it would represent a much-needed, accessible, and inexpensive treatment that may be especially relevant in low- and middle-income countries.

来源:JAMA Psychiatry,查看原文。版权归原作者所有。

引用

  1. Moore GJ, Bose N, Henter ID, et al. The 25-Year Evolution of Lithium as a Disease-Modifying Agent in Dementia: A Narrative Review. JAMA Psychiatry. 2026. PMID: 42268602. doi:10.1001/jamapsychiatry.2026.1296

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。